




# Essai Clinique

Généré le 06 mai 2024 à partir de

|                         |  |
|-------------------------|--|
| Titre                   | Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer   |
| Protocole ID            | CRC.9 (COBRA)  |
| ClinicalTrials.gov ID   | <a href="#">NCT04068103</a>  |
| Type(s) de cancer       | Côlon et rectum  |
| Phase                   | Phase II-III   |
| Type étude              | Clinique   |
| Institution             | CISSS DE LAVAL<br> HOPITAL DE LA CITE-DE-LA-SANTE<br>1755 boul. René-Laennec, Laval, QC, H7M 3L9  |
| Ville                   |  |
| Investigateur principal | Dr Nathalie Aucoin   |
| Coordonnateur           | Solange Tremblay<br>450-668-1010 poste 23603   |
| Statut                  | Fermé  |
| But étude               | This phase II/III trial studies how well circulating tumor deoxyribonucleic acid (ctDNA) testing in the blood works in predicting treatment for patients with stage IIA colon cancer after surgery. ctDNA are circulating tumor cells that are shed by tumors into the blood. Finding ctDNA in the blood means that there is very likely some small amounts of cancer that remain after surgery. However, this cancer, if detected, cannot be found on other tests usually used to find cancer, as it is too small. Testing for ctDNA levels may help identify patients with colon cancer after surgery who do benefit, and those who do not benefit, from receiving chemotherapy. |
| Critères d'éligibilité  |  |
| Critères d'exclusion    |  |